Latest news with #SunPharmaceuticals
Economic Times
23-05-2025
- Business
- Economic Times
Sun Pharma shares in focus after Q4 profit drops 19% YoY to Rs 2,154 crore
Sun Pharma's Q4 consolidated net profit fell 19% YoY to ₹2,154 crore, despite an 8% rise in revenue to ₹12,959 crore. Sequentially, both profit and revenue declined. For FY25, net profit rose to ₹10,965 crore. The company reported exceptional charges related to a U.S. settlement. Shares slipped 0.7% amid mixed financial results. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Shares of Sun Pharmaceuticals will be in focus on Friday after the drug major reported a 19% year-on-year (YoY) decline in consolidated net profit for the March quarter to Rs 2,154 crore, compared with Rs 2,659 crore in the same period last from operations rose 8% YoY to Rs 12,959 crore, up from Rs 11,983 crore in Q4FY24. However, on a sequential basis, both profit and revenue were down. PAT declined 26% from Rs 2,913 crore reported in Q3FY25, while revenue fell 5% from Rs 13,675 crore in the previous the full financial year, net profit stood at Rs 10,965 crore versus Rs 9,610 crore in Q4FY24. Meanwhile, the revenue expanded by 8.5% to Rs 52,578 crore in Q4FY25 versus Rs 48,497 crore in the quarter company reported exceptional items worth Rs 678 crore along with an exceptional tax expense of Rs 377 crore for the year ended March 31, 2025. This includes a charge of $37.44 million (Rs 316 crore), including legal expenses of $0.7 million ( Rs 5.82 crore) in the quarter ended December 31, 2024, on the agreement of a settlement in principle on the primary financial terms, with no admission of wrongdoing in the company reported expenses of Rs 9,956 crore in the quarter under review, which was 10,349 crore in Q3FY25 and Rs 9,672 crore in the year ago period. The expenses were incurred under the heads like cost of materials consumed, purchases of stock-in-trade, employee benefit expenses and finance cost. Sun Pharma shares closed at Rs 1,720 on Thursday, down 0.7% on the BSE, even as the Sensex gained 0.79%. The stock has declined 9% year-to-date but gained 84% over the last two years. Its current market capitalisation stands at Rs 4,12,675 crore.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
23-05-2025
- Business
- Time of India
Sun Pharma shares in focus after Q4 profit drops 19% YoY to Rs 2,154 crore
Sun Pharma's Q4 consolidated net profit fell 19% YoY to ₹2,154 crore, despite an 8% rise in revenue to ₹12,959 crore. Sequentially, both profit and revenue declined. For FY25, net profit rose to ₹10,965 crore. The company reported exceptional charges related to a U.S. settlement. Shares slipped 0.7% amid mixed financial results. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Shares of Sun Pharmaceuticals will be in focus on Friday after the drug major reported a 19% year-on-year (YoY) decline in consolidated net profit for the March quarter to Rs 2,154 crore, compared with Rs 2,659 crore in the same period last from operations rose 8% YoY to Rs 12,959 crore, up from Rs 11,983 crore in Q4FY24. However, on a sequential basis, both profit and revenue were down. PAT declined 26% from Rs 2,913 crore reported in Q3FY25, while revenue fell 5% from Rs 13,675 crore in the previous the full financial year, net profit stood at Rs 10,965 crore versus Rs 9,610 crore in Q4FY24. Meanwhile, the revenue expanded by 8.5% to Rs 52,578 crore in Q4FY25 versus Rs 48,497 crore in the quarter company reported exceptional items worth Rs 678 crore along with an exceptional tax expense of Rs 377 crore for the year ended March 31, 2025. This includes a charge of $37.44 million (Rs 316 crore), including legal expenses of $0.7 million ( Rs 5.82 crore) in the quarter ended December 31, 2024, on the agreement of a settlement in principle on the primary financial terms, with no admission of wrongdoing in the company reported expenses of Rs 9,956 crore in the quarter under review, which was 10,349 crore in Q3FY25 and Rs 9,672 crore in the year ago period. The expenses were incurred under the heads like cost of materials consumed, purchases of stock-in-trade, employee benefit expenses and finance cost. Sun Pharma shares closed at Rs 1,720 on Thursday, down 0.7% on the BSE, even as the Sensex gained 0.79%. The stock has declined 9% year-to-date but gained 84% over the last two years. Its current market capitalisation stands at Rs 4,12,675 crore.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
22-05-2025
- Business
- Time of India
Sun Pharma Q4 Results: Cons PAT falls 19% YoY to Rs 2,154 crore; Rs 5.5/share dividend announced
Drug major Sun Pharmaceuticals reported a 19% year-on-year decline in its Q4FY25 consolidated net profit at Rs 2,154 crore versus Rs 2,659 crore in the year ago period. The company announced a final dividend of Rs 5.50 per equity share and has fixed July 7, 2025 as the record date for the purpose of dividend. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 개수 제한, 부담 없는 임플란트 30만원 임플란트 잘하고 과잉진료 없는 치과 지금 예약 Undo The company's revenue from operations were up 8% at Rs 12,959 crore over Rs 11,983 crore reported in the corresponding quarter of the last financial year. The profit after tax (PAT) was down 26% over Rs 2,913 crore reported by the company in Q3FY25 while the topline was also 5% lower on a sequential basis versus 13,675 crore reported in the October-December quarter of FY25. More to come... Live Events
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Q4 results today: ITC, Sun Pharma, GMR Airports on May 22; see full list
ITC, Sun Pharmaceuticals, and GMR Airports will be among the 164 companies set to release their earnings report for the fourth quarter (Q4) of the financial year 2024–25 (FY25) on Thursday, May 22. These companies will also disclose their performance for the full financial year ended March 31, 2025. Other notable names announcing results today include Container Corporation of India (CONCOR), Emcure Pharmaceuticals, Honasa Consumers, Max Estates, The Ramco Cements, Reliance Home Finance, and Strides Pharma Science. Market overview May 22 Indian equity benchmarks rebounded on Wednesday, May 21. The BSE Sensex rose 410.19 points, or 0.51 per cent, to close at 81,596.63, after reaching an intraday high of 82,021.64. The Nifty50 also gained 129.55 points, or 0.52 per cent, ending the day at 24,813.45. The recovery was driven by strong performances in banking stocks such as HDFC Bank and ICICI Bank, along with positive cues from Asian markets. Today, Thursday, May 22, markets are expected to open on a cautious note. Key factors likely to influence sentiment include ongoing Q4FY25 earnings announcements, developments in the US-India trade deal, continued FII activity, and global market trends. List of firms releasing Q4 FY25 results on May 22 Accedere Limited Adishakti Loha and Ispat Ltd Adroit Infotech Limited Advance Multitech Limited Advance Petrochemicals Limited AKI India Limited Aksh Optifibre Limited Alankit Limited Alexander Stamps and Coin Limited Archidply Industries Limited Aries Agro Limited Ashiana Agro Industries Limited Asia Pack Limited Astra Microwave Products Limited Bajel Projects Limited Barbeque-Nation Hospitality Limited Bharat Gears Limited Bloom Industries Limited Blue Coast Hotels Limited BSL Limited Cargosol Logistics Limited Centum Electronics Limited Chowgule Steamships Limited Clean Science and Technology Limited Container Corporation of India Limited Continental Seeds and Chemicals Limited Daps Advertising Limited Deepak Fertilisers and Petrochemicals Corporation Limited Deepak Spinners Limited Dhunseri Tea & Industries Limited Dwarikesh Sugar Industries Limited Eldeco Housing and Industries Limited Emami Realty Limited Emcure Pharmaceuticals Limited Emerald Leasing Finance and Investment Company Limited Emerald Industries Limited Expleo Solutions Limited Fervent Synergies Limited Flair Writing Industries Limited Gandhar Oil Refinery (India) Limited Geetanjali Credit and Capital Limited Gujarat Industries Power Company Limited GMR Airports Infrastructure Limited GOCL Corporation Limited Gold Coin Health Foods Limited Goodluck India Limited Grasim Industries Limited Graviss Hospitality Limited Greenpanel Industries Limited Growington Ventures India Limited Gujarat State Petronet Limited Haryana Capfin Ltd. HFCL Ltd. (formerly Himachal Futuristic Communications Ltd.) Hindustan Motors Ltd. HLV Ltd. (formerly Hotel Leelaventure Ltd.) Honasa Consumer Ltd. HPL Electric & Power Ltd. Hubtown Ltd. (formerly Ackruti City Ltd.) India Finsec Ltd. Igarashi Motors India Ltd. India Gelatine & Chemicals Ltd. Indo Amines Ltd. Indoco Remedies Ltd. Indus Finance Ltd. Integra Switchgear Ltd. Investment & Precision Castings Ltd. ITC Ltd. Iykot Hitech Toolroom Ltd Jai Mata Glass Ltd. Jay Bharat Maruti Ltd. Jet Solar Ltd Jigar Cables Ltd. JSL Industries Ltd. Jupiter Infomedia Ltd. Kabsons Industries Ltd. Kaira Can Company Ltd. Kiran Syntex Ltd. Kriti Industries (India) Ltd. Kriti Nutrients Ltd. Kronox Lab Sciences Ltd. Labelkraft Technologies Ltd. Lincoln Pharmaceuticals Ltd. LKP Finance Ltd. Ludlow Jute & Specialities Ltd. Mahan Industries Ltd. Manba Finance Ltd. Max Estates Ltd. McNally Bharat Engineering Company Ltd. Manoj Ceramic Ltd Megasoft Ltd. Mehai Technology Ltd. Mercury Ev-Tech Ltd Metro Brands Ltd. MIC Electronics Ltd. Mishtann Foods Ltd. Morganite Crucible (India) Ltd. MTAR Technologies Ltd. Mudra Financial Services Ltd. Credo Brands Marketing Ltd. Mukat Pipes Ltd. Murae Organisor Ltd Neo Infracon Ltd NGL Fine-Chem Ltd. Nibe Ordnance and Maritime Ltd. Niraj Cement Structurals Ltd. N.R. International Ltd. Nukleus Office Solutions Ltd. Orient Bell Ltd. Orient Paper & Industries Ltd. Oswal Leasing Ltd. Padmanabh Industries Ltd. Panabyte Technologies Ltd. Panth Infinity Ltd. P.H. Capital Ltd. Power Mech Projects Ltd. Paradeep Parivahan Ltd Pradeep Metals Ltd. Premier Explosives Ltd. Premier Ltd. Radix Industries (India) Ltd. Raja Bahadur International Ltd. The Ramco Cements Ltd. Ramgopal Polytex Ltd. Ramsons Projects Ltd. Raymed Labs Ltd. Regis Industries Ltd. Reliance Home Finance Ltd. Rithwik Facility Management Services Ltd. Sandhar Technologies Ltd. Saurashtra Cement Ltd. Shalimar Wires Industries Ltd. Shervani Industrial Syndicate Ltd. Shiva Mills Ltd. Shiva Texyarn Ltd. Shree Ganesh Biotech (India) Ltd Singer India Ltd. Sharanam Infraproject and Trading Ltd Sirca Paints India Ltd. Sita Enterprises Ltd. Sarthak Metals Ltd. Southwest Pinnacle Exploration Ltd. Southern Latex Ltd. Strides Pharma Science Ltd. Subros Ltd. Sundaram Multi Pap Ltd. Sungold Capital Ltd. Sun Pharmaceutical Industries Ltd. Tainwala Chemical and Plastic (I) Ltd. Taparia Tools Ltd. TBO Tek Ltd. Tribhovandas Bhimji Zaveri Ltd. TV Today Network Ltd. Udaipur Cement Works Ltd. UFO Moviez India Ltd. Unichem Laboratories Ltd. Universal Cables Ltd. U. Y. Fincorp Ltd. Valiant Organics Ltd. Vindhya Telelinks Ltd. VMS Industries Ltd. Voith Paper Fabrics India Ltd. Walchandnagar Industries Ltd. Windlas Biotech Ltd. Wherrelz IT Solutions Ltd.
Time of India
13-05-2025
- Business
- Time of India
Pharma Cos Slip on US Move to Cut Prices
HighlightsSeveral pharmaceutical shares, including Sun Pharmaceuticals and Ajanta Pharma, underperformed on a day when the broader market saw a nearly 4 percent rally, following President Donald Trump's announcement of plans to cut US prescription drug prices by 30 to 80 percent. The Nifty Pharma Index, despite a 0.2 percent increase on the day, is down 10 percent year-to-date, contrasting with a 5 percent gain in the benchmark Nifty Index. Analysts suggest that while the proposed executive order primarily affects the branded drugs segment, which comprises 90 percent of the US market, Indian pharmaceutical companies mainly operate in the generics market, thus facing limited risks from these changes. Several pharmaceutical shares underperformed on Monday despite a strong broad market rally, after US President Donald Trump announced plans to sign an executive order slashing prescription drug prices in the US to match those in favoured nations, implying cuts of 30 per cent to 80 per cent. Sun Pharmaceuticals fell 3.2 per cent, Ajanta Pharma slipped 2.3 per cent, and Glenmark and Divi's Labs lost over 1 per cent each. Biocon dipped 0.5 per cent. The Nifty Pharma Index ended 0.2 per cent higher Monday after tumbling almost 2.4 per cent earlier in the day in response to Trump's remarks. The Sensex and Nifty jumped nearly 4 per cent—posting their biggest single-day gains in four years. Of the 20 stocks in Nifty Pharma, 13 gained and seven declined. 'The order implies a 30-80 per cent expected cut to align US drug prices with other regulated markets. But such cuts are commercially unviable for pharma firms, especially those with low-double-digit margins,' said Nikhil Ranka, CIO at Nuvama Alternates. 'That's why companies like Sun Pharma, which derives around 40 per cent revenues from the US, saw declines.' Ranka said most pharma stocks rebounded after an initial knee-jerk reaction, as the proposed changes are not expected to be immediately enforceable or impactful. 'Pharma stocks could resume their uptrend in the coming sessions,' he said. Year-to-date, the Nifty Pharma Index is down 10 per cent, compared with a 5 per cent gain in the benchmark Nifty. Bhavesh Gandhi, lead analyst for pharma and healthcare at YES Securities, said the proposed policy primarily targets the branded drugs segment, which accounts for 90 per cent of the US market. Indian companies cater mostly to the remaining 10 per cent — the generics space — where prices are already low. 'Sun Pharma, with some exposure to the branded segment, may face limited risk. But for now, the reaction is largely sentimental, and the real impact will depend on how earnings shape up,' Gandhi said.
